İçeriğe geç
akaturk Akademik ölçüm
Giriş Kayıt

OpenAlex konusu

Brain Metastases and Treatment

Bu sayfa OpenAlex konu etiketine göre çalışmaları ve o konuda görünen akademisyenleri listeler. YÖKSİS temel alan / yan dal değildir.

OpenAlex 1.701 eser 44 yazar konusu

Çalışmalar

1.701 eser

  1. Early Postoperative Mortality Risk in Cranial Tumor Surgery: Integrating Short-Term Risk With Long-Term Survival to Inform Operative Strategy 2026

    Özet henüz yok.

  2. Case Report: Beyond two years: a neurosurgical review of prolonged survival and late recurrence in IDH-wildtype GBM 2026

    IDH-wildtype glioblastoma multiforme (GBM), the most lethal primary brain tumor in adults, has a median survival of 12-15 months despite maximal multimodal therapy, including resection, radiotherapy, and chemotherapy. However, a rare subset of patients, ranging from 1% to 5%, exhibits a prognosis that defies this expe…

  3. Perioperative risk stratification after resection of brain metastases: internal development and validation of the dominant lesion surgery score in a 20-year single-center cohort 2026

    OBJECTIVE: To examine whether intracranial lesion count remains associated with survival after resection of brain metastases and to develop an internally validated perioperative risk-stratification model for early mortality in a surgically treated cohort. METHODS: We conducted a retrospective single-center cohort stud…

  4. A Specialized Importance-Aware Quantum Convolutional Neural Network with Ring-Topology (IA-QCNN) for MGMT Promoter Methylation Prediction in Glioblastoma 2026

    GBM is a highly aggressive primary malignancy in adults, necessitating personalized therapeutic strategies due to its inherent molecular heterogeneity. MGMT promoter methylation is a pivotal prognostic biomarker for anticipating response to temozolomide-based chemotherapy. Although various AI frameworks have been deve…

  5. A Specialized Importance-Aware Quantum Convolutional Neural Network with Ring-Topology (IA-QCNN) for MGMT Promoter Methylation Prediction in Glioblastoma 2026

    GBM is a highly aggressive primary malignancy in adults, necessitating personalized therapeutic strategies due to its inherent molecular heterogeneity. MGMT promoter methylation is a pivotal prognostic biomarker for anticipating response to temozolomide-based chemotherapy. Although various AI frameworks have been deve…

  6. The impact of brain metastasis and other factors on overall survival in patients with metastatic non-small cell lung cancer 2026

    Brain metastases are common in metastatic non-small cell lung cancer (NSCLC) and portend poor outcomes, yet prognostic determinants—particularly whether brain metastases are present at diagnosis or develop during follow-up—remain incompletely characterized in driver-negative patients treated with first-line platinum-b…

  7. Dural Arteriovenous Fistula (DAVF) Attributed Headache 2026

    Özet henüz yok.

  8. Clinical and radiological response assessment after whole brain radiotherapy for patients with non-small cell lung cancer with brain metastases 2026

    Aim: This study aims to evaluate the response of brain metastases to whole-brain radiotherapy (WBRT) and the role of this treatment in influencing that response.Material and Methods: The study involved eighteen patients who received WBRT for brain metastases either at the time of diagnosis or during the course of thei…

  9. Bevacizumab combined with irinotecan or temozolomide in recurrent glioblastoma: a Turkish Oncology Group (TOG) study 2026

    Özet henüz yok.

  10. Systemic–Tissue Biomarker Dissociation in Isolated Brain Metastasis From Lung Cancer: A Translational Analysis 2026

    Özet henüz yok.

  11. Dual optimization in single-isocenter radiosurgery for multiple brain metastases: a dosimetric planning study 2026

    Background This study evaluated a dual-optimization strategy for single-isocenter multiple-target stereotactic radiosurgery (SIMT-SRS) in patients with multiple brain metastases, combining target-anchored isocenter placement with individualized dose prescription for each planning target volume (PTV). Methods Three vol…

  12. The impact of extended adjuvant temozolomide beyond the standard six cycles in newly diagnosed glioblastoma 2026

    Özet henüz yok.

Akademisyenler

44 akademisyen